Hwabao WP CSI Pharmaceuticals ETF

ZLAB

09688

159570

520500

520690

159102

159929

562050

159316

Hong Kong's innovative drug sector continues to experience a downturn, with Zai Labdropping over 6% and Jiangsu Hengrui Medicinefalling more than 4%. According to Jin10, other companies such as CSPC Pharmaceutical Groupand WuXi AppTecalso saw declines.

CoinLive

Zai Lab

ZAI LAB

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

HENGRUI PHARMA

CSPC PHARMA

WUXI APPTEC

WuXi AppTec

STOCKS | Hong Kong's Innovative Drug Sector Declines

159992

512290

516500

159892

520880

159849

512010

159837

TransThera Sciences (Nanjing) has reported promising results for its multi-kinase inhibitor tinengotinib in advanced solid tumors. In a phase Ib/II study, tinengotinib achieved objective response rates of 16.7% as a monotherapy and 22.6% in combination with atezolizumab, particularly effective in cholangiocarcinoma patients. The drug demonstrated efficacy in FGFR2 fusion cases resistant to prior treatments, supporting further clinical development.

Tip Ranks

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

TRANSTHERA-B

TransThera reports promising tinengotinib results in advanced solid tumors

02359

Wuxi AppTec plans to raise approximately $1 billion through U.S. dollar-settled zero coupon convertible bonds to enhance its capacity and capabilities. The bonds, convertible to shares at an initial price of HK$153, represent about 9.1% of the enlarged H-share capital. The proceeds will be used for global expansion and corporate purposes. Morgan Stanley, Citigroup, and Goldman Sachs are advising on the issuance.

MorningStar

Morgan Stanley

Citigroup

Goldman Sachs

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GS Hldg R

Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds

603259

WUXI APPTEC plans to issue RMB6.78 billion in zero-coupon convertible bonds due 2027, with an initial conversion price of HKD153 per H share. This represents a 17.6% premium over the previous closing price. The bonds may convert into approximately 51.147 million H shares, accounting for about 9.11% of the enlarged H share capital. Estimated net proceeds are around USD1.023 billion, with 90% allocated for global expansion and 10% for general corporate purposes.

AASTOCKS News

First Trust NYSE Arca Biotech Index Fd

WUXI APPTEC  Plans to Issue RMB6.78B Convertible Bonds

02105

159859

Laekna, Inc. has scheduled its annual general meeting for June 5, 2026, in Shanghai to seek shareholder approval for its 2025 audited financial statements, the re-election of directors, and to authorize share issuance up to 20% of its issued share capital. The company aims to enhance its capital flexibility for future growth. The latest analyst rating for Laekna's stock (HK:2105) is a Buy, with a price target of HK$24.16.

LAEKNA-B

Tianhong CNI BIOMEDICINE ETF

China Southern Hang Seng Biotech ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate

Dannuo Pharmaceuticalhas launched its IPO today, offering 8.2806 million H shares at HKD75.7 each, with an entry fee of HKD3,823.17 per lot. The public offering will close on May 19, and listing is expected on May 22. The company aims to raise approximately HKD558 million, primarily for R&D and commercialization of its products. WUXI APPTEC is a cornerstone investor, holding about 5.5% of the company post-offering. Dannuo focuses on bacterial infections and has a pipeline of seven innovative projects, including two core products for treating various infections.

CITIC SEC

CITIC Securities Co., Ltd.

Orient Corporation

Dannuo Pharmaceutical  Starts IPO Today; Entry Fee HKD3,823.17 per Lot; WUXI APPTEC Participates in Early-stage Investment

BetterLife Pharma Inc. has appointed Doug Drysdale as Executive Chairman and Director. Drysdale, previously CEO of Cybin Inc., is recognized for his leadership in advancing mental healthcare. His appointment aims to enhance BetterLife's growth strategy, particularly in developing innovative therapies for neurological disorders. The company will grant him stock options for 3.5 million shares. BetterLife focuses on BETR-001, a non-hallucinogenic LSD derivative for treating neurological disorders, and is exploring further development opportunities for its drug candidate targeting viral infections.

StockTitan

Proshares UltraShort Nasdaq Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares US Pharma

VG Health

VanEck Biotech ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

SPDR S&P Health Equip

Proshares Ultra Nasdaq Biotech

Cybin

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director | BETRF Stock News

Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET | B Stock News

BlackRock, Inc.

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET | B Stock News

IBBQ

Nika Pharmaceuticals, Inc. reported a net loss of $13.36K for Q1 2026, with revenue unchanged from the prior year. The company has signed long-term agreements to enhance its product pipeline and is expanding its manufacturing capabilities in Europe. Despite no revenue-generating operations yet, Nika is preparing for production and has been funded by related-party loans. The diluted EPS remains at $0. The company is also pursuing acquisitions to bolster its product offerings.

TradingView

Invesco Nasdaq Biotechnology ETF

NIKA PHARMACEUTICALS, INC 1Q 2026: Revenue ($13.36K), Net income ($13.36K), EPS $0— 10-Q Summary

The biopharma industry faces a patent cliff crisis, risking $200–$400 billion in annual sales as patents on numerous blockbuster drugs expire between 2025 and 2030. This situation threatens revenue and poses challenges in understanding market dynamics and patient experiences. Organizations are data-rich but often lack actionable insights, leading to misaligned strategies. The complexity of healthcare decision-making and stakeholder engagement further complicates growth opportunities. As competition intensifies with the entry of generics and biosimilars, companies must develop a clearer understanding of the competitive landscape to navigate these challenges effectively.

Pharmexec

Huaan SSE 180 ETF

SPDR S&P Health

<![CDATA[The Insight Gap: Biopharma’s Hidden Risk in the Race Against the Patent Cliff]]>

Hwabao WP CSI Pharmaceuticals ETF(562050.SH)

STOCKS | Hong Kong's Innovative Drug Sector Declines

TransThera reports promising tinengotinib results in advanced solid tumors

Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds

WUXI APPTEC Plans to Issue RMB6.78B Convertible Bonds

Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate